Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$2.63 USD
-0.09 (-3.31%)
Updated May 28, 2024 03:54 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACST 2.63 -0.09(-3.31%)
Will ACST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACST
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
ACST: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA to Pay $250 Million to Settle Price-Fixing Charges
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
Other News for ACST
Acasti Pharma to Attend BIO International Convention 2024
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom